ImmuCell (ICCC) Stock Analysis & AI Equity Report
ImmuCell (ICCC) overview
ImmuCell (ICCC) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 27.6m and operating profit of USD 1.6m; the year-end share price was 6.15 USD and market capitalisation was USD 55.6m. ImmuCell is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ImmuCell's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About ImmuCell
ImmuCell develops, manufactures and commercializes animal health biologics for neonatal dairy and beef calves. Its First Defense product line uses hyperimmunized bovine colostrum to provide orally delivered antibodies against pathogens associated with calf scours. Products include single-dose boluses and gel formulations, as well as powder ingredients for calf feeding programs, and are marketed through the company’s sales organization and distributors.
Generate the ImmuCell report
ImmuCell is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ImmuCell and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on ImmuCell
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.